🧬 neoMS and neoIM – myNEO’s proprietary algorithms for presentation and immunogenicity prediction – are the core of our ImmunoEngine pipeline, enabling precise identification and selection of potent antigen targets for next-generation immunotherapies.

🎉 We’re pleased to share that the EPO has granted two methodology patents covering neoMS (EP4182928) and neoIM (EP4229640), strengthening our IP alongside our drug product-specific patents and underpinning the value of our R&D efforts.